Glyphic Biotechnologies, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Glyphic Biotechnologies, Inc. - overview
Established
2021
Location
Berkeley, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2021, Glyphic Biotechnologies, Inc. operates as a biotechnology company that sequences proteins. The company was co-founded by CEO Mr. Joshua Yang and CTO Mr.
Daniel Estandian. In February 2024, Glyphic Biotechnologies, Inc. raised USD 33. 18 million in series A funding from unspecified investors.
This round was part of a larger USD 52. 92 million venture funding. The company will use the October 2025 funding to expand its business operations.
Current Investors
OUP (Osage University Partners), ARTIS Ventures, Axial
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Medical Software
Website
www.glyphic.bio
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.